MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14760584.2024.2428800

Медицинская библиотека · Expert review of vaccines · 2024

Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study.

Nunes Baltazar, Humphreys James, Nicolay Nathalie, Braeye Toon, Van Evercooren Izaak, Holm Hansen Christian, Moustsen-Helms Ida Rask, Sacco Chiara, Fabiani Massimo, Castilla Jesús, Martínez-Baz Iván, Meijerink Hinta, Machado Ausenda, Soares Patricia, Ljung Rickard, Pihlström Nicklas, Nardone Anthony, Bacci Sabrina, Monge Susana, VEBIS-EHR working group

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/JN.1 predominance, among EU/EEA individuals with ≥65-years.

RESEARCH DESIGN AND

METHODS

We linked electronic health records to create historical cohorts in Belgium, Denmark, Italy, Navarre (Spain), Norway, Portugal and Sweden. We included individuals aged ≥65-years eligible for the autumnal 2023 COVID-19 vaccine. Follow-up started when ≥80% of country-specific sequenced viruses were BA.2.86/JN.1 (4/dec/23 to 08/jan/24) and ended 25 February 2024. At study site level, we estimated the vaccine confounder-adjusted hazard ratio (aHR) of COVID-19 hospitalizations and deaths between individuals with ≥14 days after vaccination versus unvaccinated in autumn 2023, overall, by time since vaccination and age groups. VE was estimated as (1-pooled aHR)x100 with a random-effects model.

RESULTS

XBB.1.5 VE against COVID-19 hospitalizations was 50% (95%CI: 45 to 55) and 41% (95%CI: 35 to 46) in 65-79-year-olds and in ≥80-year-olds, respectively. VE against COVID19-related-death was 58% (95%CI: 42 to 69) and 48% (95%CI: 38 to 57), respectively, in both age groups. VE estimates against each outcome declined in all age groups over time.

CONCLUSION

Monovalent XBB.1.5 vaccine had a moderate protective effect against severe and fatal COVID-19 likely caused by BA.2.86/JN.1 during the 2023/2024 winter, among persons aged ≥65.

Для цитирования: Nunes Baltazar, Humphreys James, Nicolay Nathalie, Braeye Toon, Van Evercooren Izaak, Holm Hansen Christian, Moustsen-Helms Ida Rask, Sacco Chiara, Fabiani Massimo, Castilla Jesús, Martínez-Baz Iván, Meijerink Hinta, Machado Ausenda, Soares Patricia, Ljung Rickard, Pihlström Nicklas, Nardone Anthony, Bacci Sabrina, Monge Susana, VEBIS-EHR working group. Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study.. Expert review of vaccines. 2024. DOI: 10.1080/14760584.2024.2428800.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.